All In Biotech

Drug Trial Radar · NCT05119335

A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

Phase 1/2 Open Label Dose-escalation and Expansion Trial of NKT2152 an Orally Administered HIF2α Inhibitor to Investigate Safety Pharmacokinetics Pharmacodynamics and Clinical Activity in Patients With Advanced Clear Cell Renal Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Nov 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

120

Actual

Start

Oct 26, 2021

Primary completion

Aug 22, 2025

Study completion Sep 30, 2025

Sponsor

Lead sponsor
NiKang Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of the Phase 1 portion is to identify the maximum tolerated dose (MTD) and/or the recommended doses for expansion (RDEs) of NKT2152. The Phase 2 portion will evaluate the efficacy of NKT2152 in ccRCC.

Conditions

  • ccRCC
  • Clear Cell Renal Cell Carcinoma
  • Kidney Cancer
  • Kidney Neoplasms
  • Renal Cancer
  • Renal Neoplasms
  • Recurrent Renal Cell Carcinoma
  • Metastatic Renal Cell Carcinoma
  • Refractory Renal Cell Carcinoma
  • Advanced Renal Cell Carcinoma
  • Hypoxia
  • Renal Cell Carcinoma
  • Hypoxia Inducible Factor (HIF)
  • HIF2α Inhibitor
  • Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha)
  • Hypoxia Inducible Factor 2α (HIF-2α)
  • Clear Cell

Interventions

  • Oral NKT2152Drug

    Oral HIF2α inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Dose Limiting Toxicity (DLT) events during the DLT monitoring period (first 21 days of dosing) in the Dose Escalation Phase (Phase 1)Time frame: 21 days
  2. Recommended Doses for Expansion (RDEs) Determined in the Dose Escalation Phase (Phase 1)Time frame: Approximately 2 years
  3. Objective Response Rate (ORR) determined by the Investigator in the Dose Expansion Phase (Phase 2)Time frame: Approximately 1 year
  4. Recommended Phase 2 Dose (RP2D)Time frame: Approximately 1 year

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • HonorHealth

    Scottsdale, Arizona

  • UCLA

    Los Angeles, California

  • Sarah Cannon Research Institute

    Denver, Colorado

  • Emory University

    Atlanta, Georgia

  • Indiana University Simon Comprehensive Cancer Center

    Indianapolis, Indiana

  • University of Iowa

    Iowa City, Iowa

  • National Cancer Institute

    Bethesda, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Nebraska Cancer Specialists

    Omaha, Nebraska

  • University of Oklahoma

    Oklahoma City, Oklahoma

  • Oregon Health and Science University

    Portland, Oregon

  • MD Anderson Cancer Center

    Houston, Texas

  • Seattle Cancer Care Alliance

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.